2007 Conference Sponsored by ThinkEquity Partners LLC
STAMFORD, Conn.--July 26, 2007--Delcath Systems, Inc. (Nasdaq:DCTH) today announced that its Chief Executive Officer, Richard L. Taney, will present at the upcoming ThinkBIG 2007 Conference, a gathering of top performing small cap companies sponsored by ThinkEquity Partners LLC for their institutional investor clients. The Delcath presentation is scheduled for 11:15 AM Eastern Time on Thursday, August 2, 2007. The event will be held at the Mandarin Oriental Hotel in New York City.
About Delcath Systems, Inc.
Delcath Systems is the developer of percutaneous perfusion technology
for organ- or region-specific delivery of therapeutic and chemotherapeutic
agents. The Delcath system is currently being tested with the drug melphalan
in a Phase III trial of patients with metastatic ocular and cutaneous
melanoma in the liver, and a Phase II trial of patients with primary
liver cancers and metastatic tumors in the liver from neuroendocrine
cancers and adenocarcinomas, as well as patients with melanoma who previously
received isolated perfusion. The Company's intellectual property portfolio
currently consists of 12 patents on a worldwide basis including the
U.S., Europe, Asia and Canada. For more information, please visit the
Company's website www.delcath.com.